Titre : Désensibilisation psychologique

Désensibilisation psychologique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatitis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Désensibilisation psychologique : Questions médicales les plus fréquentes", "headline": "Désensibilisation psychologique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Désensibilisation psychologique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Désensibilisation psychologique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Thérapie comportementale", "url": "https://questionsmedicales.fr/mesh/D001521", "about": { "@type": "MedicalCondition", "name": "Thérapie comportementale", "code": { "@type": "MedicalCode", "code": "D001521", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Désensibilisation et reprogrammation par mouvements oculaires", "alternateName": "Eye Movement Desensitization Reprocessing", "url": "https://questionsmedicales.fr/mesh/D057169", "about": { "@type": "MedicalCondition", "name": "Désensibilisation et reprogrammation par mouvements oculaires", "code": { "@type": "MedicalCode", "code": "D057169", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506.162" } } }, { "@type": "MedicalWebPage", "name": "Thérapie implosive", "alternateName": "Implosive Therapy", "url": "https://questionsmedicales.fr/mesh/D007171", "about": { "@type": "MedicalCondition", "name": "Thérapie implosive", "code": { "@type": "MedicalCode", "code": "D007171", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506.325" } } }, { "@type": "MedicalWebPage", "name": "Thérapie par réalité virtuelle", "alternateName": "Virtual Reality Exposure Therapy", "url": "https://questionsmedicales.fr/mesh/D063367", "about": { "@type": "MedicalCondition", "name": "Thérapie par réalité virtuelle", "code": { "@type": "MedicalCode", "code": "D063367", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.137.506.662" } } } ], "about": { "@type": "MedicalCondition", "name": "Désensibilisation psychologique", "alternateName": "Desensitization, Psychologic", "code": { "@type": "MedicalCode", "code": "D003887", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Clare Stokes", "url": "https://questionsmedicales.fr/author/Clare%20Stokes", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA." } }, { "@type": "Person", "name": "Roger L Papke", "url": "https://questionsmedicales.fr/author/Roger%20L%20Papke", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA." } }, { "@type": "Person", "name": "Marija Rowane", "url": "https://questionsmedicales.fr/author/Marija%20Rowane", "affiliation": { "@type": "Organization", "name": "Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio." } }, { "@type": "Person", "name": "Robert Hostoffer", "url": "https://questionsmedicales.fr/author/Robert%20Hostoffer", "affiliation": { "@type": "Organization", "name": "Allergy Immunology Associates, Inc., Mayfield Heights, Ohio." } }, { "@type": "Person", "name": "Hye-Ryun Kang", "url": "https://questionsmedicales.fr/author/Hye-Ryun%20Kang", "affiliation": { "@type": "Organization", "name": "Seoul National University Hospital Regional Pharmacovigilance Center, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: helenmed@snu.ac.kr." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review.", "datePublished": "2024-07-08", "url": "https://questionsmedicales.fr/article/39145084", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/tcr-23-2394" } }, { "@type": "ScholarlyArticle", "name": "The cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers.", "datePublished": "2024-07-06", "url": "https://questionsmedicales.fr/article/38977196", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jval.2024.06.019" } }, { "@type": "ScholarlyArticle", "name": "Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.", "datePublished": "2024-06-27", "url": "https://questionsmedicales.fr/article/39243730", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejca.2024.114197" } }, { "@type": "ScholarlyArticle", "name": "Treatment of intermediate-risk prostate cancer with active surveillance in the routine care-Long-term outcomes of a prospective noninterventional study (HAROW).", "datePublished": "2024-06-21", "url": "https://questionsmedicales.fr/article/39176297", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/CU9.0000000000000203" } }, { "@type": "ScholarlyArticle", "name": "Combined physical exercise re-synchronizes expression of Bmal1 and REV-ERBα and up-regulates apoptosis and metabolism in the prostate during aging.", "datePublished": "2024-06-14", "url": "https://questionsmedicales.fr/article/38880169", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.lfs.2024.122800" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Disciplines et activités comportementales", "item": "https://questionsmedicales.fr/mesh/D004191" }, { "@type": "ListItem", "position": 3, "name": "Psychothérapie", "item": "https://questionsmedicales.fr/mesh/D011613" }, { "@type": "ListItem", "position": 4, "name": "Thérapie comportementale", "item": "https://questionsmedicales.fr/mesh/D001521" }, { "@type": "ListItem", "position": 5, "name": "Désensibilisation psychologique", "item": "https://questionsmedicales.fr/mesh/D003887" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Désensibilisation psychologique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Désensibilisation psychologique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Désensibilisation psychologique", "description": "Comment diagnostiquer une phobie spécifique ?\nQuels tests sont utilisés pour évaluer l'anxiété ?\nQuels critères DSM sont utilisés pour le diagnostic ?\nComment évaluer l'impact de la peur sur la vie quotidienne ?\nQuelle est la différence entre anxiété et phobie ?", "url": "https://questionsmedicales.fr/mesh/D003887?mesh_terms=Prostatitis&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Désensibilisation psychologique", "description": "Quels sont les symptômes d'une phobie ?\nComment se manifeste l'anxiété anticipatoire ?\nQuels signes indiquent une crise d'angoisse ?\nComment reconnaître une réaction de stress aigu ?\nQuels symptômes sont associés à la désensibilisation ?", "url": "https://questionsmedicales.fr/mesh/D003887?mesh_terms=Prostatitis&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Désensibilisation psychologique", "description": "Comment prévenir le développement d'une phobie ?\nQuels rôles jouent le soutien familial dans la prévention ?\nComment la thérapie préventive peut-elle aider ?\nQuels exercices de relaxation sont recommandés ?\nComment l'éducation émotionnelle contribue-t-elle à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D003887?mesh_terms=Prostatitis&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Désensibilisation psychologique", "description": "Quels traitements sont efficaces pour la désensibilisation ?\nComment fonctionne la thérapie d'exposition ?\nQuels médicaments peuvent aider à réduire l'anxiété ?\nQuelle est l'importance de la thérapie de groupe ?\nComment la pleine conscience aide-t-elle à la désensibilisation ?", "url": "https://questionsmedicales.fr/mesh/D003887?mesh_terms=Prostatitis&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Désensibilisation psychologique", "description": "Quelles complications peuvent survenir avec une phobie non traitée ?\nComment l'anxiété chronique affecte-t-elle la santé physique ?\nQuels risques sont associés à l'automédication ?\nComment la désensibilisation peut-elle échouer ?\nQuels effets secondaires peuvent résulter des médicaments ?", "url": "https://questionsmedicales.fr/mesh/D003887?mesh_terms=Prostatitis&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Désensibilisation psychologique", "description": "Quels facteurs augmentent le risque de phobies ?\nComment le stress environnemental influence-t-il l'anxiété ?\nQuel rôle joue la génétique dans l'anxiété ?\nComment les expériences d'enfance affectent-elles l'anxiété ?\nQuels traits de personnalité sont liés à l'anxiété ?", "url": "https://questionsmedicales.fr/mesh/D003887?mesh_terms=Prostatitis&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une phobie spécifique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par l'évaluation des symptômes et l'historique médical du patient." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'anxiété ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des échelles d'anxiété comme l'échelle de Beck ou l'inventaire d'anxiété de Spielberger sont couramment utilisées." } }, { "@type": "Question", "name": "Quels critères DSM sont utilisés pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 incluent la peur intense, l'évitement et la durée des symptômes." } }, { "@type": "Question", "name": "Comment évaluer l'impact de la peur sur la vie quotidienne ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "On évalue l'impact par des questionnaires sur le fonctionnement social et professionnel." } }, { "@type": "Question", "name": "Quelle est la différence entre anxiété et phobie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété est une réponse générale, tandis que la phobie est une peur intense d'un objet ou situation spécifique." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une phobie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent la peur intense, la transpiration, le tremblement et l'évitement." } }, { "@type": "Question", "name": "Comment se manifeste l'anxiété anticipatoire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle se manifeste par une inquiétude excessive avant une situation redoutée, souvent accompagnée de symptômes physiques." } }, { "@type": "Question", "name": "Quels signes indiquent une crise d'angoisse ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent palpitations, essoufflement, vertiges et peur de perdre le contrôle." } }, { "@type": "Question", "name": "Comment reconnaître une réaction de stress aigu ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle se caractérise par des symptômes immédiats après un événement traumatique, comme l'anxiété et l'agitation." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la désensibilisation ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure une réduction de l'anxiété et une meilleure tolérance aux stimuli redoutés." } }, { "@type": "Question", "name": "Comment prévenir le développement d'une phobie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sur la gestion du stress et des techniques de relaxation peut aider à prévenir les phobies." } }, { "@type": "Question", "name": "Quels rôles jouent le soutien familial dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un soutien familial solide peut réduire le risque de développer des troubles anxieux chez les individus vulnérables." } }, { "@type": "Question", "name": "Comment la thérapie préventive peut-elle aider ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie préventive enseigne des compétences d'adaptation avant l'apparition des symptômes d'anxiété." } }, { "@type": "Question", "name": "Quels exercices de relaxation sont recommandés ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices comme la respiration profonde et la méditation peuvent aider à réduire l'anxiété." } }, { "@type": "Question", "name": "Comment l'éducation émotionnelle contribue-t-elle à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation émotionnelle aide les individus à reconnaître et gérer leurs émotions, réduisant ainsi le risque d'anxiété." } }, { "@type": "Question", "name": "Quels traitements sont efficaces pour la désensibilisation ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie cognitivo-comportementale et l'exposition graduée sont des traitements efficaces." } }, { "@type": "Question", "name": "Comment fonctionne la thérapie d'exposition ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle consiste à exposer progressivement le patient à la source de sa peur pour réduire l'anxiété." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider à réduire l'anxiété ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les antidépresseurs et les anxiolytiques sont souvent prescrits pour gérer l'anxiété." } }, { "@type": "Question", "name": "Quelle est l'importance de la thérapie de groupe ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie de groupe offre un soutien social et des stratégies d'adaptation partagées entre les participants." } }, { "@type": "Question", "name": "Comment la pleine conscience aide-t-elle à la désensibilisation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La pleine conscience aide à gérer l'anxiété en permettant au patient de se concentrer sur le moment présent." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une phobie non traitée ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'isolement social, la dépression et des troubles de l'alimentation." } }, { "@type": "Question", "name": "Comment l'anxiété chronique affecte-t-elle la santé physique ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété chronique peut entraîner des problèmes de santé comme des maladies cardiaques et des troubles digestifs." } }, { "@type": "Question", "name": "Quels risques sont associés à l'automédication ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'automédication peut aggraver les symptômes et entraîner une dépendance aux substances." } }, { "@type": "Question", "name": "Comment la désensibilisation peut-elle échouer ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La désensibilisation peut échouer si le patient ne s'engage pas pleinement dans le processus thérapeutique." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent résulter des médicaments ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure la somnolence, des nausées et des troubles de la mémoire." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de phobies ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, les expériences traumatiques et le tempérament anxieux augmentent le risque." } }, { "@type": "Question", "name": "Comment le stress environnemental influence-t-il l'anxiété ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le stress environnemental, comme les conflits familiaux, peut exacerber les symptômes d'anxiété." } }, { "@type": "Question", "name": "Quel rôle joue la génétique dans l'anxiété ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "La génétique peut prédisposer certains individus à des troubles anxieux, influençant leur réponse au stress." } }, { "@type": "Question", "name": "Comment les expériences d'enfance affectent-elles l'anxiété ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des expériences d'enfance négatives, comme l'abus, peuvent augmenter le risque de troubles anxieux à l'âge adulte." } }, { "@type": "Question", "name": "Quels traits de personnalité sont liés à l'anxiété ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des traits comme le névrosisme et la timidité sont souvent associés à un risque accru d'anxiété." } } ] } ] }

Sources (10000 au total)

Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review.

Prostate cancer (PCa) is the most common cancer in men. High-risk PCa is associated with an increased risk of PCa-related death. The combined use of androgen deprivation therapy (ADT) is essential to ... We searched for articles published in the PubMed and Scopus databases from January 1, 2005 to March 30, 2023 using the medical subject headings (MeSH) terms: prostate cancer, prostatectomy, radiation ... The study on NHT before RP for high-risk PCa found that NHT was associated with reduced adverse pathological features, such as pT3, positive surgical margins (PSM), and lymph node involvement. However... NHT for high-risk PCa does not contribute to improved oncological outcome and should not be administered easily for downstaging or PSM reduction. NHT in combination with ARSI has the potential advanta...

The cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers.

Metastatic prostate cancer (mPCa) patients with BRCA mutations benefit from targeted treatments (e.g., olaparib). Additionally, family members of affected patients have increased risk of hereditary ca... We conducted a cost-utility analysis of germline BRCA testing using two scenarios: 1) testing mPCa patients only; 2) testing mPCa patients and first-degree relatives (FDRs) of those who test positive.... Compared with no testing, BRCA testing in mPCa was associated with an incremental cost of AU$3,731 and a gain of 0.014 quality-adjusted life years (QALYs), resulting in an incremental cost-effectivene... BRCA testing when performed as a standalone strategy in patients with mPCa may not be cost-effective but demonstrates significant value for money after the inclusion of cascade testing of FDRs of muta...

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.

We performed an exploratory analysis of the SPARTAN trial to determine whether concomitant exposure to several classes of commonly prescribed medications influenced the effect of apalutamide on overal... SPARTAN was a phase III randomized controlled trial in which nmCRPC patients were randomly assigned in a 2:1 ratio to receive androgen deprivation therapy with or without apalutamide. We focused on 5 ... We did not find statistically significant differences in effect from apalutamide on OS across subgroups stratified by concomitant exposure to any of the medication classes. While there was some differ... In this post-hoc exploratory analysis of SPARTAN, effects of apalutamide on MFS and OS were consistent across subgroups stratified by exposure to concomitant medications. Exposure to concomitant metfo...

Treatment of intermediate-risk prostate cancer with active surveillance in the routine care-Long-term outcomes of a prospective noninterventional study (HAROW).

We report here the long-term outcomes of patients with intermediate-risk prostate cancer (PCa) treated with active surveillance (AS) in a daily routine setting.... HAROW (2008-2013) was a noninterventional, health service research study investigating the management of localized PCa in a community setting. A substantial proportion of the study centers were office... Of the 2957 patients enrolled, 52 with intermediate-risk PCa were managed with AS and were available for evaluation. The median follow-up was 6.8 years (interquartile range, 3.4-8.6 years). Seven pati... Although survival outcome data for intermediate-risk patients managed with AS in real-life health care conditions were promising, rates of discontinuation were high, and discontinuation was often a pa...

Combined physical exercise re-synchronizes expression of Bmal1 and REV-ERBα and up-regulates apoptosis and metabolism in the prostate during aging.

Aging increases the prevalence of prostate cancer. The circadian clock coordinates metabolism, cell cycle, and tumor suppressor p53. Although physical exercise has several effects on preventing prosta... C57BL/6 J mice were divided into 2 groups: 6 months-old (n = 10) and 18 months-old, (n = 20). The 18-month-old animals were divided into 2 subgroups: sedentary (n = 10, 18 m Sed) and submitted to comb... Combined physical exercise during aging led to increased levels of Bmal1 and decreased levels of REV-ERBα in the prostate. These results were accompanied by a reduction in the AMPK/SIRT1/PGC-1α protei... These findings suggest that strength and aerobic physical exercise may be preventive in the development of preneoplastic molecular alterations and age-related features by re-synchronizes Bmal1 and REV...

Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.

Contemporary prostate cancer (PCa) screening uses first-line prostate-specific antigen (PSA) testing, possibly followed by multiparametric magnetic resonance imaging (mpMRI) for men with elevated PSA ... To evaluate the comparative effectiveness and cost-effectiveness of first-line bpMRI versus PSA-based screening.... Decision analysis using a microsimulation model.... Surveillance, Epidemiology, and End Results database; randomized trials.... U.S. men aged 55 years with no prior screening or PCa diagnosis.... Lifetime.... U.S. health care system.... Biennial screening to age 69 years using first-line PSA testing (test-positive threshold, 4 µg/L) with or without second-line mpMRI or first-line bpMRI (test-positive threshold, PI-RADS [Prostate Imag... Screening tests, biopsies, diagnoses, overdiagnoses, treatments, PCa deaths, quality-adjusted and unadjusted life-years saved, and costs.... For 1000 men, first-line bpMRI versus first-line PSA testing prevented 2 to 3 PCa deaths and added 10 to 30 life-years (4 to 11 days per person) but increased the number of biopsies by 1506 to 4174 an... First-line PSA testing remained more cost-effective even if bpMRI was free, all men with low-risk PCa underwent surveillance, or screening was quadrennial.... Performance of first-line bpMRI was based on second-line mpMRI data.... Decision analysis suggests that comparative effectiveness and cost-effectiveness of PCa screening are driven by false-positive results and overdiagnoses, favoring first-line PSA testing with mpMRI ove... National Cancer Institute....

Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan.

Radium-223 dichloride (Ra-223) prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases. However, there is considerable variation in o... Patients with mCRPC who underwent Ra-223 treatment at Taipei Veterans General Hospital were retrospectively enrolled. Each intravenous Ra-223 dose was administered at 55 kBq/kg at four-week intervals.... Seventy-six patients underwent Ra-223 therapy; 62 patients received NHI reimbursement and the remainder self-paid. Fifty patients (65.8%) completed six cycles of treatment; 26 (34.2%) received 1‒5 cyc... Administration of Ra-223 demonstrates considerable potential to extend the survival of patients with mCRPC. Survival outcomes may be influenced by various prognostic factors. However, no significant d...

Clinical efficacy of different androgen deprivation therapies for prostate cancer and evaluation based on dynamic-contrast enhanced magnetic resonance imaging.

To evaluate the clinical efficacy of different androgen deprivation therapies for prostate cancer (PCa) based on dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI).... 104 patients with PCa were studied, all of whom were treated with androgen deprivation therapy. The patients were divided into a continuous group (continuous androgen deprivation therapy) and an inter... The objective response rate (ORR) of the intermittent group was higher than that of the continuous group (... Compared with continuous androgen deprivation therapy, intermittent androgen deprivation therapy has better clinical efficacy in the treatment of PCa, and DCE-MRI indices are related to the treatment ...